Standard BioTools (LAB) investor relations material

Executive summary

• Completed the sale of the SomaScan Business to Illumina on January 30, 2026, resulting in a significant gain and a strategic shift to focus on mass cytometry and microfluidics platforms.

• Initiated restructuring, consolidating R&D in Singapore and relocating headquarters to Boston, impacting about 20% of the workforce.

• Revenue for Q1 2026 was $21.1 million, a 5% increase year-over-year, with growth in consumables and services offsetting a decline in instruments revenue.

• Operating loss reduced by 54% and adjusted EBITDA loss improved by 78% year-over-year, reflecting successful cost-saving initiatives.

• Strong liquidity position with $524 million in cash and investments at quarter-end, excluding a $25 million earnout received after quarter close.

Financial highlights

• Total revenue for Q1 2026 was $21.1 million, up 5% year-over-year, driven by higher consumables revenue but offset by a decline in instrument sales.

• Net income for Q1 2026 was $127.1 million, compared to a net loss of $26.0 million in Q1 2025, primarily due to the gain on the SomaScan Business sale.

• Consumables revenue grew 35% year-over-year to $11.0 million, while instruments revenue declined 33% to $4.5 million.

• Operating expenses decreased 37% year-over-year to $23.8 million, reflecting lower R&D and SG&A costs due to restructuring.

• Cash, cash equivalents, and investments totaled $526.5 million at March 31, 2026, up from $213.3 million at year-end 2025.

Outlook and guidance

• Management expects existing liquidity and capital resources to be sufficient for at least the next 12 months.

• Full-year 2026 revenue is expected to be in the range of $80 million to $85 million.

• Focus remains on expanding instrument sales, growing consumables revenue, and leveraging the streamlined business post-divestiture.

• Management reiterated focus on achieving positive adjusted EBITDA by the end of 2026.